clinical trial · NCT07069569
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
Ausper Biopharma Co., Ltd.·phase2·active not recruiting·n = 127
Chronic Hepatitis BAHB-137Peg-IFNHepatitis B Vaccine
brief summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
started
May 30, 2025
primary completion
Jan 1, 2027
completion
May 1, 2027
last updated
Nov 26, 2025
official title
A Randomized, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Combination With Hepatitis B Vaccine or Pegylated Interferon α-2b (Peg-IFN) in Participants With HBeAg-Negative Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogue (NAs)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol